Showing 8241-8250 of 10142 results for "".
- DermTech Launches DermTech PLAplushttps://practicaldermatology.com/news/dermtech-launches-dermtech-plaplus/2460759/DermTech has launched DermTech PLAplus (TM), its next generation test for the enhanced early detection of melanoma, intended to provide objective and actionable information to guide clinical management decisions for skin lesions suspicious of melanoma.
- C-Jun Protein May Play Role in Psoriasis Developmenthttps://practicaldermatology.com/news/c-jun-protein-may-play-role-in-psoriasis-development/2460753/The "c-Jun" protein may play a major role in the development of psoriasis, but inhibiting this protein may alleviate symptoms, new research suggests. c-Jun belongs to a larger family of transcription factors, DNA-binding factors, known as Activator Protein-1 (AP-1). Previ
- And The Winners Are...BTL's Emsculpt Classic, Emsculpt NEO, and Emsella.https://practicaldermatology.com/news/and-the-winners-arebtls-emsculpt-classic-emsculpt-neo-and-emsella/2460751/BTL Aesthetics’ took home five awards from several aesthetic publications for Emsculpt Classic, Emsculpt NEO, and Emsella. Emsculpt therapy was named the winner of the 2020 Aestheticians Choice Award for Favorite Body Sculpting Device in Dermascop
- First Launch from FlawlessCanvas Now Availablehttps://practicaldermatology.com/news/first-launch-from-flawlesscanvas-now-available/2460750/Quantum Lift Reset Serum™ is now available from FlawlessCanvas, Inc., direct to its Facebook and Instagram followers. “The design of FlawlessCanvas Quantum Lift Reset Serum™ was based on
- Expert Opinion: Fleshing Out the Role of Biosimilars in Dermatologyhttps://practicaldermatology.com/news/expert-opinion-fleshing-out-the-role-of-biosimilars-in-dermatology/2460742/Two new studies of biosimilars of tumor necrosis factor blockers that are used to treat a number of dermatologic conditions suggest that they are equivalent to their originator drugs, but there may be more involved in making the decision about switching to a biosimilar than lower cost.
- Journey Medical to Acquire Dermira's Qbrexzahttps://practicaldermatology.com/news/journey-medical-to-acquire-dermiras-qbrexza/2460731/Journey Medical Corporation, a partner company of Fortress Biotech, Inc., has entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the US from Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company. The transaction is expected to close early in the secon
- Merz Rolls Out Belotero Balance(+) with Lidocaine in the UShttps://practicaldermatology.com/news/merz-rolls-out-belotero-balance-with-lidocaine-in-the-us/2460675/Merz Aesthetics is launching Belotero Balance(+) with Lidocaine in the US. “Healthcare providers can now rely on the well-known rheological properties and performance of Belotero Balance with the time savings and consistency of a pre-mixed lidocaine formulation,” says Patric
- MyHealthTeams' "Gaining Control with Psoriasis" Challenge Empowers Psoriasis Patients to Change Things Uphttps://practicaldermatology.com/news/myhealthteams-gaining-control-with-psoriasis-challenge-empowers-psoriasis-patients-to-change-things-up/2460663/
- Six Investigators to Receive NEA Grants for Eczema Researchhttps://practicaldermatology.com/news/six-investigators-to-receive-nea-grants-for-eczema-research/2460638/The
- Hydrafacial To Go Public After $1.1 Billion Dealhttps://practicaldermatology.com/news/hydrafacial-to-go-public-after-11-billion-deal/2460634/The HydraFacialCompany and Vesper Healthcare, a special purpose acquisition company (SPAC) co-founded by Brent Saunders, former CEO of Allergan, have entered into a definitive merger agreement. Under the terms of the agreement, HydraFacial and Vesper Healthcare will combine, and HydraFa